# V1 Empirics Check — mistralai/mistral-large-2512 (Variant C)

**Model:** mistralai/mistral-large-2512
**Variant:** C
**Date:** 2026-03-22T17:09:09.549321

---

### 1. Idea Fidelity

The paper closely adheres to the original idea manifest. It exploits the staggered transposition of the EU Preventive Restructuring Directive (2019/1023) across 26 member states to estimate its effect on bankruptcy rates using Eurostat’s *sts_rb_q* data. The identification strategy (Callaway-Sant’Anna staggered DiD), outcome variable (bankruptcy declarations index), and research question (rescue vs. reclassification) are all faithfully executed. The paper even includes the suggested robustness checks (sector-level decomposition, placebo tests, COVID controls) and addresses the theoretical ambiguity (rescue vs. stigma vs. reclassification) highlighted in the manifest.

One minor deviation: the manifest mentions 11 treatment cohorts, but the paper describes 11 cohorts over three years (likely a typo in the manifest). The data and empirical strategy are otherwise consistent with the proposed design.

---

### 2. Summary

This paper provides the first causal evaluation of the EU Preventive Restructuring Directive (2019/1023), which mandated court-supervised restructuring procedures across 26 member states. Using staggered DiD (Callaway-Sant’Anna) and Eurostat bankruptcy data, the authors find a precisely estimated null effect: the directive did not reduce aggregate bankruptcy rates (ATT = 0.10, SE = 0.25). The result is robust across specifications and suggests the reform primarily relabeled existing proceedings (reclassification) rather than rescuing viable firms. The paper challenges the European Commission’s claims about the directive’s efficacy and contributes to debates on insolvency reform, regulatory harmonization, and institutional transplantation.

---

### 3. Essential Points

#### **1. Parallel Trends Assumption: Weak Evidence and Potential Violations**
The event study (Table 4) shows pre-trends that are *noisy and not convincingly flat*. While most pre-period coefficients are statistically insignificant, the magnitude of fluctuations (e.g., -0.217 at *t-7*, 0.174 at *t-8*) is economically large relative to the null effect. The placebo test (Table 5, Panel D) yields a coefficient of 0.207 (SE = 0.191), which is not statistically significant but is *larger than the main estimate* and suggests potential confounding from post-COVID recovery trends. The authors should:
   - **Plot the event study** with 95% confidence intervals (simultaneous bands) to visually assess pre-trends. The current table is hard to interpret.
   - **Test for joint significance of pre-trends** (e.g., F-test) rather than relying on individual coefficients.
   - **Discuss whether the placebo result is concerning** or merely reflects noise. If the placebo estimate is driven by post-COVID normalization, the main result may be biased.

#### **2. Treatment Heterogeneity: Ignored but Critical**
The paper acknowledges that countries like France and Germany already had restructuring procedures, while others (e.g., Poland, Czechia) adopted genuinely new frameworks. This heterogeneity likely attenuates the ATT toward zero, but the paper does not explore it. The authors must:
   - **Estimate cohort-specific ATTs** (e.g., early vs. late adopters, countries with vs. without pre-existing procedures). If the null is driven by averaging large negative effects (e.g., Germany) with large positive effects (e.g., Poland), the aggregate result is misleading.
   - **Interact treatment with pre-existing procedure dummies** to test whether the effect differs by prior institutional context.
   - **Discuss whether the null is masking meaningful heterogeneity** or truly reflects uniform reclassification.

#### **3. Outcome Measurement: Reclassification vs. Rescue**
The bankruptcy index (*sts_rb_q*) counts *all* formal insolvency proceedings, but the directive’s goal was to shift the *composition* of proceedings (from liquidation to restructuring) without changing the total. The paper’s outcome cannot distinguish between these mechanisms. The authors should:
   - **Clarify the limitations of the outcome variable** in the abstract and introduction. The null result does not rule out compositional effects, which are arguably the directive’s primary objective.
   - **Supplement with business demography data** (e.g., Eurostat *bd_hgnace_r*) to test for changes in firm survival rates, even if the bankruptcy count is unchanged.
   - **Acknowledge that the paper’s conclusion ("reclassification") is speculative** without proceeding-level data. The null could equally reflect no effect or offsetting rescue/stigma effects.

---

### 4. Suggestions

#### **A. Strengthening the Identification**
1. **Alternative Control Groups**:
   - Use non-EU countries (e.g., UK, Switzerland) as controls to address EU-wide trends (e.g., post-COVID recovery). The current design relies on not-yet-treated EU countries, which may be affected by anticipation effects or spillovers.
   - Include a "never-treated" group (e.g., countries that transposed after the sample period) if data permits.

2. **Dynamic Effects**:
   - The event study shows a large but insignificant coefficient at *t+9* (1.846, SE = 0.567). This could reflect a delayed effect or noise. The authors should:
     - Extend the post-period to 16+ quarters to see if effects emerge later.
     - Test for non-linearities (e.g., splines) in the post-treatment period.

3. **Covariate Adjustment**:
   - The COVID stringency index is a blunt control. The authors should include:
     - Country-specific time trends to absorb unobserved heterogeneity.
     - Macroeconomic controls (e.g., GDP growth, unemployment) to address confounding from business cycles.

#### **B. Exploring Mechanisms**
1. **Reclassification Tests**:
   - If the directive relabeled proceedings, the *total* number of formal proceedings (bankruptcy + restructuring) should remain constant. The authors should:
     - Obtain data on restructuring filings (if available) and test whether the sum of bankruptcy + restructuring filings is unchanged.
     - Use business demography data to test for changes in firm exits (which would capture informal workouts).

2. **Heterogeneous Effects**:
   - **Sector-level analysis**: The paper reports sector-level results (Table 5, Panel C) but does not discuss them. Construction shows a large positive effect (0.449, SE = 0.469), which could reflect sector-specific stigma reduction. The authors should:
     - Explore why construction differs (e.g., higher leverage, cyclicality).
     - Test for heterogeneity by firm size (if data permits), as SMEs were the directive’s primary target.
   - **Country-level heterogeneity**: As noted in Essential Point 2, the authors should estimate cohort-specific ATTs.

3. **Theoretical Framework**:
   - The paper’s discussion of mechanisms (rescue, reclassification, stigma) is plausible but ad hoc. The authors should:
     - Formalize the hypotheses in a simple model (e.g., a decision tree for distressed firms).
     - Use the model to derive testable predictions (e.g., reclassification implies no change in firm exits; rescue implies fewer exits).

#### **C. Robustness and Transparency**
1. **Functional Form**:
   - The sign instability across specifications (log: +0.088, level: -29.5, Poisson: -0.134) is a red flag. The authors should:
     - Report standardized effect sizes (as in Appendix Table A1) for all specifications to facilitate comparison.
     - Justify the choice of log transformation (e.g., is the outcome log-normally distributed?).

2. **Standard Errors**:
   - The paper clusters SEs at the country level (26 clusters), which is appropriate but may understate uncertainty. The authors should:
     - Report wild bootstrap SEs (e.g., Cameron et al. 2008) to address small-cluster bias.
     - Test for spatial correlation (e.g., Conley SEs) given the EU’s integrated markets.

3. **Data and Code**:
   - The paper should include:
     - A replication package with code and data (even if Eurostat data requires a license).
     - A table of transposition dates (currently buried in the text).
     - A map of transposition timelines to visualize staggered adoption.

#### **D. Framing and Interpretation**
1. **Policy Implications**:
   - The paper’s conclusion ("the directive had no effect") is too strong given the limitations. The authors should:
     - Emphasize that the null result does not rule out compositional effects or heterogeneous impacts.
     - Discuss whether the directive’s benefits (e.g., reduced stigma, improved restructuring outcomes) are observable in other outcomes (e.g., firm survival, employment).

2. **Literature Comparison**:
   - The paper cites single-country studies (e.g., Ponticelli & Alencar 2016, Vig 2013) but does not compare effect sizes. The authors should:
     - Benchmark their null result against prior findings (e.g., Brazil’s court reform reduced exits by 20%).
     - Discuss why the EU’s harmonization effort failed where single-country reforms succeeded (e.g., treatment intensity, institutional inertia).

3. **Alternative Explanations**:
   - The paper focuses on reclassification but does not rule out other explanations for the null:
     - **Implementation lags**: Courts and practitioners may need years to adapt.
     - **Low take-up**: Firms may not use the new procedures due to lack of awareness or high costs.
     - **Offsetting effects**: Rescue and stigma effects may cancel out.
   The authors should discuss these alternatives and suggest ways to test them (e.g., survey data on take-up rates).

#### **E. Minor but Important**
1. **Abstract Clarity**:
   - The abstract states the result is "consistent with the reclassification hypothesis," but this is speculative. Rephrase to: "The null result is consistent with reclassification, though proceeding-level data are needed to confirm this mechanism."

2. **Table Formatting**:
   - Table 3 (event study) is hard to read. Use a figure instead, with event time on the x-axis and ATT on the y-axis, with 95% CIs.
   - Table 2 (main results) should include the number of treated units in each specification.

3. **COVID Controls**:
   - The COVID stringency index is included but not discussed. The authors should:
     - Report the coefficient on the stringency index (currently omitted from Table 2).
     - Test whether the null result is driven by COVID-related disruptions (e.g., estimate the model without 2020-2021).

4. **JEL Codes**:
   - Add *C23* (Panel Data Models) and *K35* (Bankruptcy Law) to reflect the econometric and legal focus.

---

### Final Assessment
This is a well-executed paper with a compelling research design and a null result that challenges conventional wisdom. The core identification strategy is sound, but the parallel trends assumption and treatment heterogeneity require closer scrutiny. The paper’s main weakness is its speculative interpretation of the null (reclassification) without proceeding-level data. With the suggested improvements—especially cohort-specific ATTs, alternative control groups, and a deeper exploration of mechanisms—this could be a publishable *AER: Insights* paper. As is, it falls short of the journal’s standards for robustness and nuance. **Revise and resubmit with major revisions.**
